GlassScriptPhysician profile
James C Buswinka
NPI 1396729448
$1,728.33
in general payments reported to CMS, 2019-2025
29 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.03 · 2020: $19.42 · 2022: $56.97 · 2023: $353 · 2024: $759 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,494 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,493.92 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $197.68 | 2023-2025 | Duopa |
| Novartis Pharmaceuticals Corporation | $155.50 | 2023-2025 | |
| Celgene Corporation | $148.92 | 2023-2025 | Zeposia |
| Biogen, INC. | $133.70 | 2023-2025 | Tysabri, Skyclarys |
| Janssen Biotech, INC. | $94.99 | 2025 | |
| Ucb, INC. | $94.83 | 2024-2025 | Briviact, Fintepla |
| Amneal Pharmaceuticals LLC | $94.64 | 2024-2025 | Crexont |
| Sk Life Science, INC. | $93.27 | 2022-2024 | |
| Vanda Pharmaceuticals INC. | $82.79 | 2024-2025 | Ponvory |
| Argenx US, INC. | $68.08 | 2023-2024 | Vyvgart Hytrulo, Vyvgart |
| Emd Serono, INC. | $51.77 | 2019 | |
| Pfizer INC. | $47.79 | 2023-2024 | |
| Neurelis, INC. | $47.77 | 2024 | Valtoco |
| Tanabe Pharma America, INC. | $45.70 | 2024 | |
| Tg Therapeutics, INC. | $44.53 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $35.34 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $30.15 | 2024 | Acthar |
| Otter Pharmaceuticals, LLC | $28.26 | 2025 | Sympazan |
| Alexion Pharmaceuticals, INC. | $28.14 | 2025 | Ultomiris |
| Merz Pharmaceuticals, LLC | $25.06 | 2025 | Xeomin, Inbrija |
| Ipsen Biopharmaceuticals, INC | $24.97 | 2022 | |
| Genentech USA, INC. | $24.82 | 2025 | Ocrevus Zunovo |
| Acorda Therapeutics, INC | $22.86 | 2023 | Inbrija |
| Jazz Pharmaceuticals INC. | $20.14 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.42 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $19.02 | 2024 | |
| Boston Scientific Corporation | $18.95 | 2024 | |
| Lilly USA, LLC | $17.98 | 2023 | Amyvid |
| Supernus Pharmaceuticals, INC. | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Buswinka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.